Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dilara Z. Gatina has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A Biosafety Study of Human Umbilical Cord Blood Mononuclear Cells Transduced with Adenoviral Vector Carrying Human Vascular Endothelial Growth Factor cDNA In Vitro

    by Ilnur I. Salafutdinov, Dilara Z. Gatina, Maria I. Markelova, Ekaterina E. Garanina, Sergey Yu. Malanin, Ilnaz M. Gazizov, Andrei A. Izmailov, Albert A. Rizvanov, Rustem R. Islamov, András Palotás, et al.

    The biosafety of gene therapy remains a crucial issue for both the direct and cell-mediated delivery of recombinant cDNA encoding biologically active molecules for the pathogenetic correction of congenital or acquired disorders. The diversity of vector systems and cell carriers for the delivery of therapeutic genes revealed the difficulty of developing and implementing a safe and effective drug containing artificial genetic material for the treatment of human diseases in practical medicine. Therefore, in this study we assessed changes in the transcriptome and secretome of umbilical cord blood mononuclear cells (UCB-MCs) genetically modified using adenoviral vector (Ad5) carrying cDNA encoding human vascular endothelial growth factor (VEGF165) or reporter green fluorescent protein (GFP). A preliminary analysis of UCB-MCs transduced with Ad5-VEGF165 and Ad5-GFP with MOI of 10 showed efficient transgene expression in gene-modified UCB-MCs at mRNA and protein levels. The whole transcriptome sequencing of native UCB-MCs, UCB-MC+Ad5-VEGF165, and UCB-MC+Ad5-GFP demonstrated individual sample variability rather than the effect of Ad5 or the expression of recombinant vegf165 on UCB-MC transcriptomes. A multiplex secretome analysis indicated that neither the transduction of UCB-MCs with Ad5-GFP nor with Ad5-VEGF165 affects the secretion of the studied cytokines, chemokines, and growth factors by gene-modified cells. Here, we show that UCB-MCs transduced with Ad5 carrying cDNA encoding human VEGF165 efficiently express transgenes and preserve transcriptome and secretome patterns. This data demonstrates the biosafety of using UCB-MCs as cell carriers of therapeutic genes.


  • Open Access

    Induction of Angiogenesis by Genetically Modified Human Umbilical Cord Blood Mononuclear Cells

    by Dilara Z. Gatina, Ilnaz M. Gazizov, Margarita N. Zhuravleva, Svetlana S. Arkhipova, Maria A. Golubenko, Marina O. Gomzikova, Ekaterina E. Garanina, Rustem R. Islamov, Albert A. Rizvanov, Ilnur I. Salafutdinov

    Stimulating the process of angiogenesis in treating ischemia-related diseases is an urgent task for modern medicine, which can be achieved through the use of different cell types. Umbilical cord blood (UCB) continues to be one of the attractive cell sources for transplantation. The goal of this study was to investigate the role and therapeutic potential of gene-engineered umbilical cord blood mononuclear cells (UCB-MC) as a forward-looking strategy for the activation of angiogenesis. Adenovirus constructs Ad-VEGF, Ad-FGF2, Ad-SDF1α, and Ad-EGFP were synthesized and used for cell modification. UCB-MCs were isolated from UCB and transduced with adenoviral vectors. As part of our in vitro experiments, we evaluated the efficiency of transfection, the expression of recombinant genes, and the secretome profile. Later, we applied an in vivo Matrigel plug assay to assess engineered UCB-MC’s angiogenic potential. We conclude that hUCB-MCs can be efficiently modified simultaneously with several adenoviral vectors. Modified UCB-MCs overexpress recombinant genes and proteins. Genetic modification of cells with recombinant adenoviruses does not affect the profile of secreted pro- and anti-inflammatory cytokines, chemokines, and growth factors, except for an increase in the synthesis of recombinant proteins. hUCB-MCs genetically modified with therapeutic genes induced the formation of new vessels. An increase in the expression of endothelial cells marker (CD31) was revealed, which correlated with the data of visual examination and histological analysis. The present study demonstrates that gene-engineered UCB-MC can be used to stimulate angiogenesis and possibly treat cardiovascular disease and diabetic cardiomyopathy.


  • Open Access

    Co-Expression of VEGF and FGF2 Mediated by Multigenic Plasmid Constructs Promotes Blood Flow Restoration in a Rat Model of Hind Limb Ischemia

    by Dilara Gatina, Ekaterina Garanina, Margarita Zhuravleva, Angelina Titova, Ilnur Salafutdinov

    Peripheral arterial disease (PAD) is characterized by stenosis and occlusion of the arteries leading to poor blood supply to the limb. Patients with PAD suffer pain at rest, intermittent claudication, skin ulcers, and gangrene. The end-stage of the disease could lead to limb amputation despite optimal medical and surgical management. The delivery of angiogenic factors to restore tissue perfusion is an attractive strategy, both as a primary and adjunctive treatment for PAD. We synthesized multigenic plasmid constructs expressing combinations of VEGF, FGF2, and DsRed genes:pVax1-VEGF-FGF2-DsRed, pVax1-VEGF-DsRed, pVax1-FGF2-DsRed, and pVax1-DsRed. In the constructed vectors, gene sequences are linked through the furin-containing 2A-peptide sequence of picornaviruses. Plasmid vector pVax1 is approved by the FDA for use in clinical trials. Previously, we confirmed the functionality of the developed non-viral constructs and the synthesis of VEGF, FGF2, and DsRed proteins by transfected cells. At this stage, we injected plasmid constructs into rat muscles after hind limb ischemia. Quantitative analysis of serum cytokines and chemokines of experimental and control groups on 3, 14, and 21 days after plasmids injection showed no significant differences in the secretion of the 18 cytokines studied. We observed a gradual increase in volumetric blood flow in the experimental groups, despite decreased expression of VEGF and FGF2 on 14 and 21 days. On day 21, the maximum increase in volumetric blood flow was in the pVax1-VEGF-FGF2-DsRed group. In turn, the maximum number of capillaries at 21 days was in the pVax1-VEGF-DsRed group. Capillary density was increased in pVax1-VEGF-FGF2-DsRed and pVax1-FGF2-DsRed groups compared to control groups. We also observed low expression levels of caspase-3 and caspase-9 in the muscles of the experimental groups. Thus, co-expression of VEGF and FGF2 stimulates angiogenic and regenerative processes in a rat model of hind limb ischemia. In addition, the results of this study are consistent with our previous work and confirm the effectiveness of using systems based on 2A-peptide sequences for transgene co-expression. The study of the serum cytokine profile showed the absence of adverse immune effects, indicating the safety of the non-viral constructs used. These results suggest the possibility of using these non-viral constructs to enhance therapeutic angiogenesis in the treatment of ischemic diseases. This paper has been supported by the Kazan Federal University Strategic Academic Leadership Program (PRIORITY-2030).

  • Open Access

    Proangiogenic Effect of 2A-Peptide Based Multicistronic Recombinant Constructs Encoding VEGF and FGF2 Growth Factors

    by Dilara Z. Gatina, Ekaterina E. Garanina, Margarita N. Zhuravleva, Gulnaz E. Synbulatova, Adelya F. Mullakhmetova, Valeriya V. Solovyeva, Andrey P. Kiyasov, Catrin S. Rutland, Albert A. Rizvanov, Ilnur I. Salafutdinov

    Coronary artery disease remains one of the primary healthcare problems due to the high cost of treatment, increased number of patients, poor clinical outcomes, and lack of effective therapy. Though pharmacological and surgical treatments positively affect symptoms and arrest the disease progression, they generally exhibit a limited effect on the disease outcome. The development of alternative therapeutic approaches towards ischemic disease treatment, especially of decompensated forms, is therefore relevant. Therapeutic angiogenesis, stimulated by various cytokines, chemokines, and growth factors, provides the possibility of restoring functional blood flow in ischemic tissues, thereby ensuring the regeneration of the damaged area. In the current study, based on the clinically approved plasmid vector pVax1, multigenic constructs were developed encoding vascular endothelial growth factor (VEGF), fibroblast growth factors (FGF2), and the DsRed fluorescent protein, integrated via picornaviruses’ furin-2A peptide sequences. In vitro experiments demonstrated that genetically modified cells with engineered plasmid constructs expressed the target proteins. Overexpression of VEGF and FGF2 resulted in increased levels of the recombinant proteins. Concomitantly, these did not lead to a significant shift in the general secretory profile of modified HEK293T cells. Simultaneously, the secretome of genetically modified cells showed significant stimulating effects on the formation of capillary-like structures by HUVEC (endothelial cells) in vitro. Our results revealed that when the multicistronic multigene vectors encoding 2A peptide sequences are created, transient transgene co-expression is ensured. The results obtained indicated the mutual synergistic effects of the growth factors VEGF and FGF2 on the proliferation of endothelial cells in vitro. Thus, recombinant multicistronic multigenic constructs might serve as a promising approach for establishing safe and effective systems to treat ischemic diseases.


  • Open Access

    Influence of Recombinant Codon-Optimized Plasmid DNA Encoding VEGF and FGF2 on Co-Induction of Angiogenesis

    by Ilnur I. Salafutdinov, Ilnaz M. Gazizov, Dilara K. Gatina, Ruslan I. Mullin, Alexey A. Bogov, Rustem R. Islamov, Andrey P. Kiassov, Ruslan F. Masgutov, Albert A. Rizvanov

    Several methods for the stimulation of skin wound repair have been proposed over the last few decades. The most promising among them are gene and stem cell therapy. Our present experiments combined several approaches via the application of human umbilical cord blood mononuclear cells (hUCB-MC) that were transfected with pBud-VEGF165-FGF2 plasmid (gene-cell therapy) and direct gene therapy using pBud-VEGF165-FGF2 plasmid to enhance healing of full thickness skin wounds in rats. The dual expression cassette plasmid pBud-VEGF165-FGF2 encodes both VEGF and FGF2 therapeutic genes, expressing pro-angiogenic growth factors. Our results showed that, with two weeks post-transplantation, some transplanted cells still retained expression of the stem cell and hematopoietic markers C-kit and CD34. Other transplanted cells were found among keratinocytes, hair follicle cells, endothelial cells, and in the derma. PCNA expression studies revealed that transplantation of transfected cells terminated proliferative processes in regenerating wounds earlier than transplantation of untransfected cells. In the direct gene therapy group, four days post-operatively, the processes of flap revascularization, while using Easy LDI Microcirculation Camera, was higher than in control wounded skin. We concluded that hUCB-MC can be used for the treatment of skin wounds and transfection these cells with VEGF and FGF2 genes enhances their regenerative abilities. We also concluded that the application of pBud-VEGF165-FGF2 plasmids is efficient for the direct gene therapy of skin wounds by stimulation of wound revascularization.